Results from two separate phase I/II studies investigating the pan-RAS inhibitor daraxonrasib suggest it is safe and effective for patients with pancreatic ductal adenocarcinoma, building on recently announced data showcasing the drug's superior performance in a phase III study. Together, these new data are an exciting sign that daraxonrasib could become the first targeted pancreatic cancer therapy to spur sustained responses.
A 2026 study studied this question.